OPTO CIRCUITS (INDIA) LIMITED.

SENSING TECHNOLOGY

A15778 A16673 A16674 ISO 9001:2000 ISO 13485:2003 ISO 14001:2004 OHSAS 18001:2007

OPTO CIRCUITS (INDIA) LTD.

Date: 21st January 2011

THE NATIONAL STOCK EXCHANGE
EXCHANGE PLAZA
BANDRA KURLA COMPLEX
BANDRA [E]
MUMBAI – 400 051.

Dear Sir,

We would like to inform you that the Company's wholly owned German subsidiary Eurocor GmbH presented its latest development in second generation PTA balloon technology – FREEWAY 014™ and FREEWAY 035™ – to the German market for the very first time at the LINC (Leipzig Interventional Course) on 20 January 2011. The two new products already premiered in London in November 2010.

The German launch of Eurocor's new FREEWAY products is scheduled to take place at the "Symposium on drug-coated balloons for peripheral interventions: SFA and below the knee". International experts will be presenting and discussing the latest developments in connection with treatment involving drug-eluting balloons at this symposium.

We are enclosing herewith the press release in this regard.

Thanking you,

Yours faithfully.
for OPTO CIRCUITS (INDIA) LTD.,

Authorised Signatory.

Plot No. 83, Electronics City, Bangalore - 560 100.
Phone : +91-80-28521040-41-42 Fax : +91-80-28521094
E-mail : oci@optoindia.com, info@optoindia.com Web: www.optoindia.com

Eurocor

Opto Circuits (India) Limited

Opto Circuits subsidiary ready to launch its solutions for treating peripheral arterial disease (PAD) in Germany

21 January 2011 | Bonn, Germany | Bengaluru, India

Opto Circuits (India) Ltd.'s Bonn-based subsidiary Eurocor GmbH presented its latest development in second generation PTA balloon technology – FREEWAY 014™ and FREEWAY 035™ – to the German market for the very first time at the LINC (Leipzig Interventional Course) on 20 January 2011. The two new products already premiered in London in November 2010.

The German launch of Eurocor's new FREEWAY products is scheduled to take place at the "Symposium on drug-coated balloons for peripheral interventions: SFA and below the knee". International experts will be presenting and discussing the latest developments in connection with treatment involving drug-eluting balloons at this symposium.

Expert Discussion

The scientific debate will be headed by the renowned physician and consultant angiologist from Berlin, Prof. Dr. Karl-Ludwig Schulte. Presentations will include a live transmission of an intervention involving a drug-eluting balloon as well as a paper delivered by the cell biologist PD Dr. Kirsten Peters from Rostock on the unique new coating technology. Lectures by other well-known physicians on the advantages of drug-eluting balloons to treat various indications, including below-the-knee dilations, will go to round off the programme.

Alternative to Amputation

FREEWAY 014™ was primarily developed for treating critical limb ischaemia associated with peripheral arterial disease (PAD). The primary amputation rate among diabetes mellitus patients with critical limb ischaemia linked to PAD can amount to as much as 40%. Thanks to Eurocor's FREEWAY® DEB balloon interventionalists now have access to a treatment option that constitutes a valid alternative to amputation and can additionally help to save up to US$50,000 per patient per year.

"We are delighted to be able to present our latest developments to a large specialist audience in Leipzig. FREEWAY is the next logical step of our successful Eurocor technologies." said Katja Hausner, Director Business Affairs at Eurocor.

About: Eurocor GmbH

Eurocor GmbH is a rapidly growing European Life Sciences Technology corporation specialising in the research, development and manufacture of interventional cardiology products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular devices.

The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimisation of clinically effective technologies. For more information, please visit www.eurocor.de.

Follow us at http://twitter.com/Eurocor_Germany



Eurocor

Opto Circuits (India) Limited

About: Opto Circuits (India) Limited

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCUI

Website: www.optoindia.com

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are Cardiac Science, Criticare, Eurocor, Ormed, Mediaid and Unetixs. The company's key markets are North America, Europe and BRIC countries.

Contact	
Opto Circuits India Ltd. E: Media - media@optoindia.com; Investors - ir@optoindia.com T: +91 80 2852 8088	Adfactors PR Neha Goenka E: neha.goenka@adfactorspr.com T: +91 22 2281 3565

